

Elecsys Progesterone III



REF		SYSTEM
07092539 190	100	MODULAR ANALYTICS E170 cobas e 411 cobas e 601 cobas e 602

English

System information

For **cobas e 411** analyzer: test number 1380
 For MODULAR ANALYTICS E170, **cobas e 601** and **cobas e 602** analyzers: Application Code Number 235

Intended use

Immunoassay for the in vitro quantitative determination of progesterone in human serum and plasma.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and **cobas e** immunoassay analyzers.

Summary

The gestagen progesterone is a steroid hormone which is mainly formed in the cells of the corpus luteum and during pregnancy in the placenta.

The progesterone concentration correlates with the development and regression of the corpus luteum. Whereas progesterone is barely detectable in the follicular phase of the female cycle, a rise in the progesterone level is observed one day prior to ovulation. Increased progesterone synthesis occurs during the luteal phase. In the second half of the cycle pregnanediol is excreted in urine as the main degradation product of progesterone.¹

Progesterone brings about the conversion of the uterine mucosa into a tissue rich in glands (secretion phase), in order to prepare for the intrauterine implantation of the fertilized ovum. During pregnancy, progesterone inhibits the contraction of the myometrium. In the mammary gland, progesterone (together with estrogens) promotes the proliferation, secretion and disposition of the alveoli.^{1,2,3,4}

The determination of progesterone is utilized in fertility diagnosis for the detection of ovulation and assessment of the luteal phase.⁵

Test principle

Competition principle. Total duration of assay: 18 minutes.

- 1st incubation: By incubating the sample (20 µL) with a progesterone-specific biotinylated antibody, immunocomplexes are formed, the amount of which is dependent upon the analyte concentration in the sample.
- 2nd incubation: After addition of streptavidin-coated microparticles and an progesterone derivative labeled with a ruthenium complex^{a)}, the still-vacant sites of the biotinylated antibodies become occupied, with formation of an antibody-hapten complex. The entire complex becomes bound to the solid phase via interaction of biotin and streptavidin.
- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent barcode or e-barcode.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)₃²⁺)

Reagents - working solutions

The reagent rackpack is labeled as PROG III.

- M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL:
 Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Anti-progesterone-Ab~biotin (gray cap), 1 bottle, 10 mL:
 Biotinylated monoclonal anti-progesterone antibody (recombinant, sheep) 30 ng/mL, phosphate buffer 25 mmol/L, pH 7.0; preservative.

- R2 Progesterone-peptide~Ru(bpy)₃²⁺ (black cap), 1 bottle, 9 mL:

Progesterone (of vegetable origin) coupled to a synthetic peptide labeled with ruthenium complex, 2 ng/mL; phosphate buffer 25 mmol/L, pH 7.0; preservative.

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

Reagent handling

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is read in from the respective reagent barcodes.

Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the Elecsys reagent kit **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	12 weeks
on the analyzers	8 weeks

Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Li-heparin, K₂-EDTA and K₃-EDTA plasma. Li-heparin plasma tubes containing separating gel can be used.

Criterion: slope 0.9-1.1 + intercept within ± 0.1 ng/mL + coefficient of correlation (Pearson) ≥ 0.95 .

Stable for 1 day at 20-25 °C, 5 days at 2-8 °C, 6 months at -20 °C (± 5 °C). Freeze only once.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Do not use heat-inactivated samples.

Do not use samples and controls stabilized with azide.

Ensure the samples, calibrators and controls are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples, calibrators and controls on the analyzers should be analyzed/measured within 2 hours.

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

- [REF] 07092547190, Progesterone III CalSet, for 4 x 1 mL

Elecsys Progesterone III



- [REF] 11731416190, PreciControl Universal, for 4 x 3 mL
- [REF] 03028542122, Diluent Estradiol/Progesterone, 2 x 22 mL sample diluent

General laboratory equipment

Accessories for **cobas e 411** analyzer:

- [REF] 11662988122, ProCell, 6 x 380 mL system buffer
- [REF] 11662970122, CleanCell, 6 x 380 mL measuring cell cleaning solution
- [REF] 11930346122, Elecsys SysWash, 1 x 500 mL washwater additive
- [REF] 11933159001, Adapter for SysClean
- [REF] 11706802001, AssayCup, 60 x 60 reaction cups
- [REF] 11706799001, AssayTip, 30 x 120 pipette tips
- [REF] 11800507001, Clean-Liner

Accessories for MODULAR ANALYTICS E170, **cobas e 601** and **cobas e 602** analyzers:

- [REF] 04880340190, ProCell M, 2 x 2 L system buffer
- [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF] 03023141001, PC/CC-Cups, 12 cups to prewarm ProCell M and CleanCell M before use
- [REF] 03005712190, ProbeWash M, 12 x 70 mL cleaning solution for run finalization and rinsing during reagent change
- [REF] 03004899190, PreClean M, 5 x 600 mL detection cleaning solution
- [REF] 12102137001, AssayTip/AssayCup, 48 magazines x 84 reaction cups or pipette tips, waste bags
- [REF] 03023150001, WasteLiner, waste bags
- [REF] 03027651001, SysClean Adapter M

Accessories for all analyzers:

- [REF] 11298500316, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use. Read in the test-specific parameters via the reagent barcode. If in exceptional cases the barcode cannot be read, enter the 15-digit sequence of numbers (except for the **cobas e 602** analyzer).

MODULAR ANALYTICS E170, **cobas e 601** and **cobas e 602** analyzers: PreClean M solution is necessary.

Bring the cooled reagents to approximately 20 °C and place on the reagent disk (20 °C) of the analyzer. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the bottles.

Calibration

Traceability: The Elecsys Progesterone III assay is traceable via ID-GC/MS (isotope dilution gas chromatography/mass spectrometry) to highly purified progesterone by weight analogously to BCR-348R and ERM-DA347.⁶

Every Elecsys reagent set has a barcoded label containing specific information for calibration of the particular reagent lot. The predefined master curve is adapted to the analyzer using the relevant CalSet.

Calibration frequency: Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the reagent kit was registered on the analyzer).

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Renewed calibration is recommended as follows:

- after 1 month (28 days) when using the same reagent lot
- after 7 days (when using the same reagent kit on the analyzer)
- as required: e.g. quality control findings outside the defined limits

Quality control

For quality control, use PreciControl Universal.

In addition, other suitable control material can be used.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

The analyzer automatically calculates the analyte concentration of each sample (either in nmol/L, ng/mL or in µg/L).

Conversion factors: $\text{nmol/L} \times 0.314 = \text{ng/mL} (\mu\text{g/L})$
 $\text{ng/mL} \times 3.18 = \text{nmol/L}$

Limitations - interference

The assay is unaffected by icterus (bilirubin ditaurate $\leq 923 \mu\text{mol/L}$ or $\leq 54 \text{ mg/dL}$), hemolysis ($\text{Hb} \leq 0.621 \text{ mmol/L}$ or $\leq 1.0 \text{ g/dL}$), lipemia (Intralipid $\leq 200 \text{ mg/dL}$) and biotin ($\leq 123 \text{ nmol/L}$ or $\leq 30 \text{ ng/mL}$).

Criterion: Recovery within $\pm 10 \%$ of initial value with samples $> 2 \text{ ng/mL}$, $\pm 15 \%$ with samples > 0.5 to 2 ng/mL and $\leq \pm 0.2 \text{ ng/mL}$ with samples $\leq 0.5 \text{ ng/mL}$.

Visibly turbid samples give a false low result.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. $> 5 \text{ mg/day}$) until at least 8 hours following the last biotin administration.

No interference was observed from rheumatoid factors up to a concentration of 1200 IU/mL.

In vitro tests were performed on 16 commonly used pharmaceuticals. Of these, only phenylbutazone at therapeutic dosage levels showed interference with the assay (progesterone values depressed). No interference was observed with clomiphene citrate.

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

Limits and ranges

Measuring range

0.159-191 nmol/L or 0.05-60 ng/mL (defined by the Limit of Detection and the maximum of the master curve). Values below the Limit of Detection are reported as $< 0.159 \text{ nmol/L}$ or $< 0.05 \text{ ng/mL}$. Values above the measuring range are reported as $> 191 \text{ nmol/L}$ or $> 60 \text{ ng/mL}$.

Lower limits of measurement

Limit of Blank, Limit of Detection and Limit of Quantitation

Limit of Blank = 0.080 nmol/L (0.025 ng/mL)

Limit of Detection = 0.159 nmol/L (0.05 ng/mL)

Limit of Quantitation = 0.636 nmol/L (0.2 ng/mL)

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A requirements.

The Limit of Blank is the 95th percentile value from $n \geq 60$ measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples. The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

Elecsys Progesterone III

The Limit of Quantitation is defined as the lowest amount of analyte in a sample that can be accurately quantitated with a total allowable error of $\leq 20\%$.

Dilution

Samples with progesterone concentrations above the measuring range can be diluted with Diluent Estradiol/Progesterone or a suitable human serum with a low analyte concentration. The recommended dilution is 1:10. The concentration of the diluted sample must be > 6 nmol/L (> 2 ng/mL).

After dilution, multiply the result by the dilution factor.

Depending on the biological variance of the diluted patient sample and the human serum matrix used for production of Diluent Estradiol/Progesterone, lower recovery of diluted samples may be observed.

Expected values

The expected ranges were determined by testing specimens drawn from 147 apparently healthy males, 142 apparently healthy, post-menopausal women over the age of 50, and from 416 apparently healthy pregnant women between the ages of 17 and 45 (137 in the first trimester, 140 in the second trimester, and 139 in the third trimester). The expected range for healthy women was determined by weekly blood drawing over a period of 3 months from 26 apparently healthy women between the ages of 18 and 45 that were not taking any hormonal contraceptives. Based on a central 90% interval, the following ranges were obtained:

Test subjects	N	5 th percentile nmol/L	Median nmol/L	95 th percentile nmol/L
Healthy men	147	< 0.159	< 0.159	0.474
Healthy women				
Follicular phase	117	0.181	0.588	2.84
Ovulation phase	38	0.385	1.60	38.1
Luteal phase	126	5.82	31.9	75.9
Postmenopause	142	< 0.159	< 0.159	0.401
Healthy pregnant women				
1 st trimester	137	35.0	76.3	141
2 nd trimester	140	80.8	151	264
3 rd trimester	139	187	340	681

Test subjects	N	5 th percentile ng/mL	Median ng/mL	95 th percentile ng/mL
Healthy men	147	< 0.05	< 0.05	0.149
Healthy women				
Follicular phase	117	0.057	0.185	0.893
Ovulation phase	38	0.121	0.503	12.0
Luteal phase	126	1.83	10.0	23.9
Postmenopause	142	< 0.05	< 0.05	0.126
Healthy pregnant women				
1 st trimester	137	11.0	24.0	44.3
2 nd trimester	140	25.4	47.5	83.3
3 rd trimester	139	58.7	107	214

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using Elecsys reagents, pooled human sera and controls in a protocol (EP5-A2) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days ($n = 84$). The following results were obtained:

cobas e 411 analyzer					
Sample	Mean		SD		CV
	nmol/L	ng/mL	nmol/L	ng/mL	%
Human serum 1	0.700	0.220	0.083	0.026	11.8
Human serum 2	2.34	0.737	0.080	0.025	3.3
Human serum 3	9.48	2.98	0.232	0.073	2.5
Human serum 4	65.7	20.7	1.39	0.437	2.1
Human serum 5	164	51.6	2.04	0.642	1.2
PreciControl U ^b 1	24.7	7.78	0.477	0.150	1.9
PreciControl U2	51.4	16.2	1.37	0.432	2.7

b) U = Universal

cobas e 411 analyzer					
Sample	Mean		SD		CV
	nmol/L	ng/mL	nmol/L	ng/mL	%
Human serum 1	0.700	0.220	0.162	0.051	23.1
Human serum 2	2.34	0.737	0.245	0.077	10.4
Human serum 3	9.48	2.98	0.490	0.154	5.2
Human serum 4	65.7	20.7	2.33	0.734	3.6
Human serum 5	164	51.6	5.93	1.87	3.6
PreciControl U1	24.7	7.78	0.910	0.286	3.7
PreciControl U2	51.4	16.2	2.16	0.680	4.2

MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers					
Sample	Mean		SD		CV
	nmol/L	ng/mL	nmol/L	ng/mL	%
Human serum 1	0.502	0.158	0.060	0.019	11.9
Human serum 2	2.35	0.739	0.124	0.039	5.3
Human serum 3	4.68	1.47	0.175	0.055	3.7
Human serum 4	28.5	8.96	0.836	0.263	2.9
Human serum 5	174	54.6	4.15	1.30	2.4
PreciControl U1	24.9	7.84	0.566	0.178	2.3
PreciControl U2	50.8	16.0	1.27	0.399	2.5

MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers					
Sample	Mean		SD		CV
	nmol/L	ng/mL	nmol/L	ng/mL	%
Human serum 1	0.502	0.158	0.113	0.036	22.5
Human serum 2	2.35	0.739	0.193	0.061	8.2
Human serum 3	4.68	1.47	0.306	0.096	6.5
Human serum 4	28.5	8.96	1.11	0.349	3.9
Human serum 5	174	54.6	5.72	1.80	3.3
PreciControl U1	24.9	7.84	0.785	0.247	3.2
PreciControl U2	50.8	16.0	1.69	0.531	3.3

Method comparison

A comparison of the Elecsys Progesterone III assay (y) with ID-GC/MS (x) gave the following correlations (ng/mL):

Number of samples measured: 40

Elecsys Progesterone III

Passing/Bablok⁷

$$y = 0.993x + 0.011$$

$$r = 0.943$$

The sample concentrations were between 0.541 and 179 nmol/L (0.17 and 56.3 ng/mL).

Analytical specificity

For the Elecsys Progesterone III assay, the following cross-reactivities (CR; in %) were found at the respective additive concentration (AC; in ng/mL), tested with progesterone concentrations of approximately 0.4 ng/mL and 5.5 ng/mL:

	CR (%)	AC (ng/mL)
Androstendiol	n. d. ^{c)}	4000
Androstendione	n. d.	80
Aldosterone	n. d.	1000
Allopregnanolone	0.362	2000
Corticosterone	0.682	200
Cortisol	0.004	20000
Danazol	0.001	100000
DHEA-S	n. d.	16000
Norgestrel	n. d.	1000
Estradiol	n. d.	400
Ethisterone	0.002	1000
Ethinodiol diacetate	n. d.	1000
Medroxyprogesterone	n. d.	5000
Norethindrone	n. d.	1000
Norethindrone acetate	n. d.	1000
Testosterone	0.075	2000
21-Deoxycortisol	0.079	2000
11-Deoxycorticosterone	3.93	600
11-Deoxycortisol	0.014	6000
5- α -Dihydrotestosterone	0.24	20
5- β -Dihydroprogesterone	0.247	240
Pregnenolone	0.423	16000
Pregnanolone	0.119	2000
Medroxyprogesterone acetate	0.012	1000
6 α -Methylprednisolone	n. d.	1000
17 α -Hydroxypregnenolone	0.007	2000
17 α -Hydroxyprogesterone	n. d.	2000
20 α -Hydroxy-4-pregnen-3-one	0.670	250

c) n. d. = not detectable

References

- 1 Johnson MR, Carter G, Grint C, et al. Relationship between ovarian steroids, gonadotrophins and relaxin during the menstrual cycle. *Acta Endocrinol* 1993;129:121-125.
- 2 Laufer N, Navot D, Schenker JG. The pattern of luteal phase plasma progesterone and estradiol in fertile cycles. *Am J Obstet Gynecol* 1982;143:808-813.
- 3 Veldhuis JD, Christiansen E, Evans WS, et al. Physiological profiles of episodic progesterone release during the midluteal phase of the human menstrual cycle: analysis of circadian and ultradian rhythms, discrete pulse properties, and correlations with simultaneous luteinizing hormone release. *J Clin Endocrinol Metab* 1988;66(2):414-421.
- 4 Filicori M, Butler JP, Crowley WF Jr. Neuroendocrine regulation of the corpus luteum in the human. *J Clin Invest* 1984;73:1638-1647.







- 5 Guillaume J, Benjamin F, Sicuranza B, et al. Maternal serum levels of estradiol, progesterone and h-Choriongonadotropin in ectopic pregnancy and their correlation with endometrial histologic findings *Surg Gynecol Obstet* 1987;165:9-12.
- 6 Thienpont L, Siekmann L, Lawson A, et al. Development, Validation and Certification by Isotope Dilution Gas Chromatography-Mass Spectrometry of Lyophilized Human Serum Reference Materials for Cortisol (CRM 192 and 193) and Progesterone (CRM 347 and 348). *Clin Chem* 1991;37(4):540-546.
- 7 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets, the product information and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see <https://usdiagnostics.roche.com> for definition of symbols used):

	Contents of kit
	Analyzers/Instruments on which reagents can be used
	Reagent
	Calibrator
	Volume after reconstitution or mixing
	Global Trade Item Number

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPIID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2018, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

